Xiaomin Wan

1.3k total citations
71 papers, 1.0k citations indexed

About

Xiaomin Wan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Xiaomin Wan has authored 71 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 21 papers in Economics and Econometrics. Recurrent topics in Xiaomin Wan's work include Cancer Immunotherapy and Biomarkers (18 papers), Economic and Financial Impacts of Cancer (17 papers) and Health Systems, Economic Evaluations, Quality of Life (11 papers). Xiaomin Wan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Economic and Financial Impacts of Cancer (17 papers) and Health Systems, Economic Evaluations, Quality of Life (11 papers). Xiaomin Wan collaborates with scholars based in China, Australia and United Kingdom. Xiaomin Wan's co-authors include Liubao Peng, Chongqing Tan, Xiaohui Zeng, Xia Luo, Yucong Zhang, Lidan Yi, Jianhe Li, Sini Li, Qiao Liu and Peng Ye and has published in prestigious journals such as PLoS ONE, Cancer and Physical Chemistry Chemical Physics.

In The Last Decade

Xiaomin Wan

70 papers receiving 1000 citations

Peers

Xiaomin Wan
Chongqing Tan China
Liubao Peng China
Pedro Nazareth Aguiar Brazil
A. Brewster United Kingdom
Marcus A. Neubauer United States
Timothée Olivier Switzerland
Meghan Shea United States
Mihaela Mates Canada
Laura Marandino Italy
Waqar Haque United States
Chongqing Tan China
Xiaomin Wan
Citations per year, relative to Xiaomin Wan Xiaomin Wan (= 1×) peers Chongqing Tan

Countries citing papers authored by Xiaomin Wan

Since Specialization
Citations

This map shows the geographic impact of Xiaomin Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomin Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomin Wan more than expected).

Fields of papers citing papers by Xiaomin Wan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomin Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomin Wan. The network helps show where Xiaomin Wan may publish in the future.

Co-authorship network of co-authors of Xiaomin Wan

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomin Wan. A scholar is included among the top collaborators of Xiaomin Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomin Wan. Xiaomin Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Andong, et al.. (2024). Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States. Frontiers in Immunology. 15. 1464092–1464092. 4 indexed citations
2.
Ma, Jing, Sini Li, Chongqing Tan, et al.. (2024). Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study. PharmacoEconomics. 42(12). 1345–1357. 1 indexed citations
3.
Wu, Mei-Yu, Jing Ma, Xuehong Wang, et al.. (2024). Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study. Clinical and Molecular Hepatology. 31(2). 394–408. 2 indexed citations
4.
Ye, Peng, Liting Wang, Liubao Peng, et al.. (2023). Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Clinical Therapeutics. 45(10). 965–972. 3 indexed citations
5.
6.
7.
8.
Liu, Qiao, Xia Luo, Zhen Zhou, et al.. (2021). PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China. Frontiers in Oncology. 11. 745493–745493. 3 indexed citations
9.
Li, Sini, Jianhe Li, Liubao Peng, et al.. (2021). First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. Clinical Therapeutics. 43(7). 1253–1264.e5. 3 indexed citations
10.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology. 11. 743765–743765. 4 indexed citations
11.
Li, Sini, Jianhe Li, Liubao Peng, Yamin Li, & Xiaomin Wan. (2021). Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 684073–684073. 10 indexed citations
12.
Li, Sini, Liubao Peng, Chongqing Tan, et al.. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 15(5). e0232240–e0232240. 22 indexed citations
13.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2020). Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 10(11). e040691–e040691. 8 indexed citations
14.
15.
Zeng, Xiaohui, Xiaomin Wan, Liubao Peng, et al.. (2019). Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 9(12). e031019–e031019. 17 indexed citations
16.
Chen, Jun, Gaoyun Hu, Zhuo Chen, et al.. (2019). Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Clinical Drug Investigation. 39(10). 931–938. 28 indexed citations
17.
Wan, Xiaomin, et al.. (2016). Experimental study of ginseng, astragalus and liquorice against myocardial injury induced by adriamycin. 50(3). 82. 1 indexed citations
18.
Jia, Fengjuan, Xiaomin Wan, Wei Zhu, et al.. (2015). Overexpression of Mitochondrial Phosphate Transporter 3 Severely Hampers Plant Development through Regulating Mitochondrial Function in Arabidopsis. PLoS ONE. 10(6). e0129717–e0129717. 40 indexed citations
19.
Zeng, Xiaohui, Jianhe Li, Liubao Peng, et al.. (2014). Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis. PLoS ONE. 9(2). e88881–e88881. 23 indexed citations
20.
Tan, Chongqing, Liubao Peng, Xiaohui Zeng, et al.. (2013). Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China. PLoS ONE. 8(12). e83396–e83396. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chongqing Tan Breakdown of academic impact, for papers by Liubao Peng Breakdown of academic impact, for papers by Pedro Nazareth Aguiar Breakdown of academic impact, for papers by A. Brewster Breakdown of academic impact, for papers by Marcus A. Neubauer Breakdown of academic impact, for papers by Timothée Olivier Breakdown of academic impact, for papers by Meghan Shea Breakdown of academic impact, for papers by Mihaela Mates Breakdown of academic impact, for papers by Laura Marandino Breakdown of academic impact, for papers by Waqar Haque
Rankless by CCL
2026